VIP Peptide Suppresses the Dangerous Th17 Immune Response in Autoimmune Disease
VIP (vasoactive intestinal peptide) specifically regulated Th17 cell function in autoimmune inflammation, suppressing the IL-17-producing cells that drive multiple autoimmune diseases — a targeted anti-autoimmune mechanism.
Quick Facts
What This Study Found
VIP suppressed Th17 cell differentiation and IL-17 production in autoimmune inflammation models, specifically targeting the pathogenic Th17 response that drives rheumatoid arthritis, EAE (MS model), and other autoimmune diseases — precision anti-autoimmune peptide therapy.
Key Numbers
How They Did This
animal-study study on neuropeptides, inflammation.
Why This Research Matters
Relevant for neuropeptides, inflammation, immune-function.
The Bigger Picture
Advances peptide research.
What This Study Doesn't Tell Us
See abstract.
Questions This Raises
- ?Further research needed.
- ?Clinical translation to evaluate.
Trust & Context
- Key Stat:
- Key finding VIP suppressed Th17 cell differentiation and IL-17 production in autoimmune inflammation models, specifically targeting the pathogenic Th17 response t
- Evidence Grade:
- moderate evidence.
- Study Age:
- Published in 2007.
- Original Title:
- Vasoactive intestinal peptide regulates Th17 function in autoimmune inflammation.
- Published In:
- Neuroimmunomodulation, 14(3-4), 134-8 (2007)
- Authors:
- Leceta, Javier(4), Gomariz, Rosa P(3), Martinez, Carmen, Carrión, Mar, Arranz, Alicia, Juarranz, Yasmina
- Database ID:
- RPEP-01256
Evidence Hierarchy
Tests effects in animals (usually mice or rats), not humans.
What do these levels mean? →Frequently Asked Questions
What was studied?
VIP Peptide Suppresses the Dangerous Th17 Immune Response in Autoimmune Disease
What was found?
VIP (vasoactive intestinal peptide) specifically regulated Th17 cell function in autoimmune inflammation, suppressing the IL-17-producing cells that drive multiple autoimmune diseases — a targeted anti-autoimmune mechanism.
Read More on RethinkPeptides
Cite This Study
https://rethinkpeptides.com/research/RPEP-01256APA
Leceta, Javier; Gomariz, Rosa P; Martinez, Carmen; Carrión, Mar; Arranz, Alicia; Juarranz, Yasmina. (2007). Vasoactive intestinal peptide regulates Th17 function in autoimmune inflammation.. Neuroimmunomodulation, 14(3-4), 134-8.
MLA
Leceta, Javier, et al. "Vasoactive intestinal peptide regulates Th17 function in autoimmune inflammation.." Neuroimmunomodulation, 2007.
RethinkPeptides
RethinkPeptides Research Database. "Vasoactive intestinal peptide regulates Th17 function in aut..." RPEP-01256. Retrieved from https://rethinkpeptides.com/research/leceta-2007-vasoactive-intestinal-peptide-regulates
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.